SEC backs Sino­vac's case against ac­tivist in­vestor who tried to take over; Blue­bird pen­cils in $400M raise

→ An ac­tivist in­vestor in Sino­vac — one of the Chi­nese biotechs lead­ing the race to de­vel­op a Covid-19 vac­cine — has been charged by the SEC for cook­ing up a se­cret plan to take con­trol of the com­pa­ny with­out dis­clos­ing his own­ings. Ji­aqiang “Chi­ang” Li and his firm, 1Globe Cap­i­tal, agreed to pay civ­il penal­ties to­tal­ing $290,000 with­out ad­mit­ting or deny­ing the SEC’s find­ings. Sino­vac and Li have been en­tan­gled in law­suits since 2018, which is still on­go­ing in An­tigua and Bar­bu­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER